Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): A Creutzfeldt-Jakob Disease (CJD) Lookback Study: Assessing the Risk of Blood Borne Transmission of Classic Forms of Creutzfeldt-Jakob Disease, Funding Opportunity Announcement (FOA) CK09-002, Initial Review, 23867-23868 [E9-11905]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 97 / Thursday, May 21, 2009 / Notices
dwashington3 on PROD1PC60 with NOTICES
Name: Meeting on Pre-Clinical
Research Supported by the Special
Statutory Funding Program for Type 1
Diabetes Research.
Place: National Institutes of Health,
Neuroscience Building, 6001 Executive
Blvd., Conference Room C, Bethesda,
MD 20852.
Date: June 18, 2009.
Open: 8 a.m. to 8:30 a.m.
Agenda: Overview of the Cooperative
Study Group for Autoimmune Disease
Prevention (Prevention Centers)
research program.
Closed: 8:30 a.m. to 9 a.m.
Agenda: Mid-course assessment of the
Prevention Centers.
Open: 9 a.m. to 9:30 a.m.
Agenda: Overview of the
Immunobiology of Xenotransplantation
Cooperative Research Program (IXCRP)
research program.
Closed: 9:30 a.m. to 10:15 a.m.
Agenda: Mid-course assessment of the
IXCRP.
Open: 10:30 a.m. to 11 a.m.
Agenda: Overview of the NHP
Transplantation Tolerance Cooperative
Study Group (NHPCSG).
Closed: 11 a.m. to 12:15 p.m.
Agenda: Mid-course assessment of the
NHPCSG; discussion of cross-cutting
themes for strengthening the ongoing
preclinical research portfolio.
Open: 12:30 p.m. to 1:30 p.m.
Agenda: Discussion of future
opportunities for preclinical research.
Contact Person: Julie Wallace, PhD,
Health Science Policy Analyst, Office of
Scientific Program and Policy Analysis,
National Institute of Diabetes and
Digestive and Kidney Diseases, 9000
Rockville Pike, Building 31, Room
9A05, Bethesda, MD 20892, (301) 496–
6623, wallaceja@niddk.nih.gov.
Please Note: The NIH has instituted
security measures to ensure the safety of NIH
employees and property. Upon your arrival at
the Neuroscience Building, enter through the
main lobby where you will be greeted at the
security guard’s desk. Visitors who are not
NIH employees will be required to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to have their bags searched
in order to enter the building. You will then
be issued a visitor badge. In estimating your
travel time, please allow for these security
measures, particularly if you are arriving in
a group. Self-parking is available for a
maximum of $8 per day.
A registration link, information about
the meeting, and the agenda are
available online: https://
www3.niddk.nih.gov/fund/
otherType1Diabetes09/.
VerDate Nov<24>2008
13:08 May 20, 2009
Jkt 217001
Dated: May 12, 2009.
Sanford Garfield,
Executive Secretary, DMICC, Division of
Diabetes, Endocrinology and Metabolic
Diseases, NIDDK, National Institutes of
Health.
[FR Doc. E9–11698 Filed 5–20–09; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Arthritis and Musculoskeletal and Skin
Diseases Special Emphasis Panel, Mentored
Career Development, Institutional Research
Training & Pathways to Independence
Reviews.
Date: June 5, 2009.
Time: 11 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892. (Telephone
Conference Call)
Contact Person: Charles H. Washabaugh,
PhD, Scientific Review Administrator,
Review Branch, NIAMS/NIH, 6701
Democracy Blvd., Room 816, Bethesda, MD
20892, 301–451–4838,
washabac@mail.nih.gov.
Name of Committee: National Institute of
Arthritis and Musculoskeletal and Skin
Diseases Special Emphasis Panel, Building
Interdisciplinary Research Team (BIRT) II
RFA.
Date: June 12, 2009.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892. (Virtual
Meeting)
Contact Person: Charles H. Washabaugh,
EP Review Branch NIAMS, One Democracy
Plaza, Suite 800, MSC 4872, 6701 Democracy
Plaza, Bethesda, MD 20892–4872, 301–496–
9568, washabac@mail.nih.gov.
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
23867
Name of Committee: National Institute of
Arthritis and Musculoskeletal and Skin
Diseases Special Emphasis Panel,
Competitive Revision Reviews.
Date: June 24, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Contact Person: Michael L. Bloom, Ph.D.,
MBA, Scientific Review Administrator, EP
Review Branch, NIH/NIAMS, One
Democracy Plaza, Room 820, MSC 4872,
6701 Democracy Blvd., Bethesda, MD 20892–
4872, 301–594–4953,
Michael_Bloom@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS)
Dated: May 14, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–11831 Filed 5–20–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): A CreutzfeldtJakob Disease (CJD) Lookback Study:
Assessing the Risk of Blood Borne
Transmission of Classic Forms of
Creutzfeldt-Jakob Disease, Funding
Opportunity Announcement (FOA)
CK09–002, Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting.
Time and Date: 12 p.m.–3 p.m., June 5,
2009 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters to be Discussed: The meeting will
include the initial review, discussion, and
evaluation of ‘‘ A Creutzfeldt-Jakob Disease
Lookback Study: Assessing the Risk of Blood
Borne Transmission of Classic Forms of
Creutzfeldt-Jakob Disease, FOA CK09–002.’’
Contact Person for More Information:
Wendy Carr, Ph.D., CDC, 1600 Clifton Road,
NE., Mailstop D60, Atlanta, GA 30333,
Telephone: (404) 498–2276.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
E:\FR\FM\21MYN1.SGM
21MYN1
23868
Federal Register / Vol. 74, No. 97 / Thursday, May 21, 2009 / Notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: May 15, 2009.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E9–11905 Filed 5–20–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS)
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Meeting
dwashington3 on PROD1PC60 with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Arthritis and Musculoskeletal
and Skin Diseases Advisory Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Arthritis and
Musculoskeletal and Skin Diseases Advisory
Council.
Date: June 2, 2009.
Open: 8 a.m. to 12 p.m.
Agenda: To discuss administrative details
relating to the Council’s business and special
Reports.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 6, Bethesda, MD 20892.
Closed: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 6, Bethesda, MD 20892.
Contact Person: Susana Serrate-Sztein, MD,
Director, Division of Skin and Rheumatic
Diseases, NIAMS/NIH, 6701 Democracy
Blvd., Suite 800, Bethesda, MD 20892–4872.
(301) 594–5032. szteins@mail.nih.gov.
VerDate Nov<24>2008
13:08 May 20, 2009
Jkt 217001
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Dated: May 14, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–11830 Filed 5–20–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel VMD–ARRA
Competive Revision Applications
Date: May 29, 2009.
Time: 11 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Washington, DC,
1515 Rhode Island Avenue, NW.,
Washington, DC 20005.
Contact Person: Jian, Wang, PhD, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 4095D, MSC 7812, Bethesda,
MD 20892, (301) 435–2778,
wangjia@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Drug
Discover ARRA CR.
Date: May 29, 2009.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Mayflower Park Hotel, 405 Olive
Way, Seattle, WA 98101.
Contact Person: Hungyi Shau, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6186,
MSC 7804, Bethesda, MD 20892, 301–435–
1720, shauhung@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Special
Emphasis Panel for KNOD Revision
Applications.
Date: June 2, 2009.
Time: 3 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: New Orleans Marriott at the
Convention Center, 859 Convention Center
Boulevard, New Orleans, LA 70130.
Contact Person: Fungai F. Chanetsa, MPH,
PhD, Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3135,
MSC 7770, Bethesda, MD 20892, 301–435–
1262, chanetsaf@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Epidemiology of Cancer Revision
Applications.
Date: June 3, 2009.
Time: 9 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Alexandria Old Town, 1767
King Street, Alexandria, VA 22314.
Contact Person: Denise Wiesch, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3150,
MSC 7770, Bethesda, MD 20892, (301) 435–
0684, wieschd@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Lung
Toxicology ARRA CR.
Date: June 3, 2009.
Time: 11 a.m. to l p.m.
Agenda: To review and evaluate grant
applications.
Place: Warwick Seattle Hotel, 401 Lenora
Street, Seattle, WA 98121.
Contact Person: Ghenima Dirami, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4112,
E:\FR\FM\21MYN1.SGM
21MYN1
]]>Agencies
[Federal Register Volume 74, Number 97 (Thursday, May 21, 2009)]
[Notices]
[Pages 23867-23868]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-11905]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): A Creutzfeldt-Jakob Disease (CJD) Lookback Study:
Assessing the Risk of Blood Borne Transmission of Classic Forms of
Creutzfeldt-Jakob Disease, Funding Opportunity Announcement (FOA) CK09-
002, Initial Review
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the aforementioned meeting.
Time and Date: 12 p.m.-3 p.m., June 5, 2009 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance
with provisions set forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director, Management Analysis
and Services Office, CDC, pursuant to Public Law 92-463.
Matters to be Discussed: The meeting will include the initial
review, discussion, and evaluation of `` A Creutzfeldt-Jakob Disease
Lookback Study: Assessing the Risk of Blood Borne Transmission of
Classic Forms of Creutzfeldt-Jakob Disease, FOA CK09-002.''
Contact Person for More Information: Wendy Carr, Ph.D., CDC,
1600 Clifton Road, NE., Mailstop D60, Atlanta, GA 30333, Telephone:
(404) 498-2276.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices
[[Page 23868]]
pertaining to announcements of meetings and other committee
management activities, for both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: May 15, 2009.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. E9-11905 Filed 5-20-09; 8:45 am]
BILLING CODE 4163-18-P
